指南与共识胸部CT

胸部CT对接受分子靶向药物和免疫检查点抑制剂患者药物相关性肺炎的诊断与临床管理:Fleischner学会立场文件

Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society.
PubMed 文献 · Radiology · 2021-01-12

Fleischner学会立场文件阐述分子靶向药物和免疫检查点抑制剂相关药物性肺炎(DRP)的胸部CT诊断与临床管理。DRP诊断通常需排除其他已知病因,CT表现按影像模式分为急性(弥漫性肺泡损伤)、短暂性(单纯性肺嗜酸性粒细胞增多症)、亚急性间质性病变(机化性肺炎、过敏性肺炎)和慢性间质性病变(非特异性间质性肺炎)。文件提供诊断标准和管理推荐。

要点

  • DRP的CT表现按影像模式分为急性、短暂性、亚急性和慢性间质性病变四类。
  • 单一药物可 associated with 多种影像模式,需结合分布评估。
  • DRP诊断通常通过排除其他已知病因实现。

关键影像表现/征象

  • CT模式反映急性(弥漫性肺泡损伤)间质性肺炎和短暂性(单纯性肺嗜酸性粒细胞增多症)肺部异常。
  • CT模式反映亚急性间质性病变(机化性肺炎和过敏性肺炎)。
  • CT模式反映慢性间质性病变(非特异性间质性肺炎)。
  • 单一药物可 associated with 多种影像模式。
  • 影像特征评估需考虑肺实质异常的分布(影像模式方法)。

诊断标准与关键数值

  • DRP诊断通常通过排除其他潜在已知病因实现。
  • CT模式分类:急性(弥漫性肺泡损伤)、短暂性(单纯性肺嗜酸性粒细胞增多症)、亚急性间质性病变(机化性肺炎和过敏性肺炎)、慢性间质性病变(非特异性间质性肺炎)。

临床应用与阅片要点

  • 对接受分子靶向药物或免疫检查点抑制剂的患者,阅片时应按影像模式方法评估肺实质异常分布。
  • 需认识单一药物可 associated with 多种影像模式,避免仅凭单一模式排除DRP。
  • 诊断DRP需结合排除其他潜在已知病因。
  • 治疗疑似DRP患者通常包括停药、免疫抑制治疗或两者兼有,并支持治疗如补充氧气和重症监护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Use of molecular targeting agents and immune checkpoint inhibitors (ICIs) has increased the frequency and broadened the spectrum of lung toxicity, particularly in patients with cancer. The diagnosis of drug-related pneumonitis (DRP) is usually achieved by excluding other potential known causes. Awareness of the incidence and risk factors for DRP is becoming increasingly important. The severity of symptoms associated with DRP may range from mild or none to life-threatening with rapid progression to death. Imaging features of DRP should be assessed in consideration of the distribution of lung parenchymal abnormalities (radiologic pattern approach). The CT patterns reflect acute (diffuse alveolar damage) interstitial pneumonia and transient (simple pulmonary eosinophilia) lung abnormality, subacute interstitial disease (organizing pneumonia and hypersensitivity pneumonitis), and chronic interstitial disease (nonspecific interstitial pneumonia). A single drug can be associated with multiple radiologic patterns. Treatment of a patient suspected of having DRP generally consists of drug discontinuation, immunosuppressive therapy, or both, along with supportive measures eventually including supplemental oxygen and intensive care. In this position paper, the authors provide diagnostic criteria and management recommendations for DRP that should be of interest to radiologists, clinicians, clinical trialists, and trial sponsors, among others. This article is a simultaneous joint publication in Radiology and CHEST. The articles are identical except for stylistic changes in keeping with each journal's style. Either version may be used in citing this article. Published under a CC BY 4.0 license. Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Johkoh T, Lee KS, Nishino M, et al. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology. 2021. PMID: 33434111. doi:10.1148/radiol.2021203427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。